%0 Journal Article
%T A randomized, exploratory molecular imaging study targeting amyloid ¦Â with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study
%A Alan Rembach
%A Christopher C. Rowe
%A Christopher Fowler
%A Craig Ritchie
%A Kevin J. Barnham
%A Keyla Perez
%A Michael Woodward
%A Olivier Salvado
%A Paul Maruff
%A Pierrick Bourgeat
%A Robert Cherny
%A Rudy Tanzi
%A Svetlana Bozinosvski
%A Victor L. Villemagne
%J Archive of "Alzheimer's & Dementia : Translational Research & Clinical Interventions".
%D 2017
%R 10.1016/j.trci.2017.10.001
%X We are developing a second generation 8-OH quinoline (2-(dimethylamino) methyl-5, 7-dichloro-8-hydroxyquinoline [PBT2, Prana Biotechnology]) for targeting amyloid ¦Â (A¦Â) in Alzheimer's disease (AD). In an earlier phase IIa, 3 month trial, PBT2 lowered cerebrospinal fluid A¦Â by 13% and improved cognition (executive function) in a dose-related fashion in early AD. We, therefore, sought to learn whether PBT2 could alter the A¦Â-PET signal in subjects with prodromal or mild AD, in an exploratory randomized study over a 12-month phase in a double-blind and a 12-month open label extension phase trial design
%K Randomised control trial
%K Alzheimer's disease
%K A¦Â-amyloid PET molecular imaging
%K Novel 8-OH quinoline
%K Clinical trial design
%K Biomarkers for Alzheimer's disease
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702880/